iTeos Therapeutics (ITOS) PT Raised to $46 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth raised the price target on iTeos Therapeutics (NASDAQ: ITOS) to $46.00 (from $44.00) while maintaining a Buy rating.

The analyst commented: "On May 10, iTeos reported 1Q24 financial results and provided a corporate update. For 1Q24, the company reported no revenues, in line with consensus estimates, and a net loss of $1.07 per share, compared to the consensus estimated a net loss of $0.98 per share. We update our model to reflect reported financials. For 2024, we project no revenues and a net loss of $4.70 per share. We maintain our Buy rating of ITOS and raise our 12-month price target to $46 from prior $44 per diluted share as a result of the recent cash infusion."

You May Also Be Interested In

• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Piper Sandler Reiterates Overweight Rating on KKR (KKR), 'highest conviction name'